Followers | 2540 |
Posts | 250759 |
Boards Moderated | 35 |
Alias Born | 05/06/2014 |
Tuesday, October 25, 2016 8:51:34 PM
Many small cap biotech stocks like Pharmacyte Biotech Inc (OTCQB: PMCB) call themselves “clinical stage biotech stock.” Here is what you need to know when a biotech stock says they are in the clinical stage.
If you are an investor new to biotech investing, you might be wondering what is meant when a small cap biotech stock like Pharmacyte Biotech Inc (OTCQB: PMCB) calls themselves a “clinical stage biotech stock” or company. After all, many small cap biotech stocks like Pharmacyte Biotech are still in the clinical stage; but such stocks tend to not be the best of investments for risk adverse or novice investors.
What Are Clinical Stage Biotech Stocks?
When a small cap biotech stock calls themselves a clinical stage biotech stock, it usually means they do not yet have any drugs or treatments approved by the FDA or other appropriate regulatory authorities in other countries. For that reason, you should be aware of and have an understanding of the phases of drug development:
An Investigational New Drug Application (IND) is made to the FDA showing results of any study done in the laboratory.
Clinical Phase I involves studies performed on a small group of healthy volunteers to see how a new drug is metabolized in the human body as well as to determine the dose and dosage interval that will have a positive effect on the disease or problem without unwanted side-effects.
Clinical Phase II involves treating a larger group of patients to demonstrate a new drug's efficacy and to confirm its safety with comparisons often being made with another group receiving inactive placebo treatment.
Clinical Phase III’s main goal is to prove that any promising effects seen in Phase II can also be obtained in larger patient groups with great importance being attached to safety issues, documentation and production preparations.
Submission of a New Drug Application to the FDA will usually occur at this point and it should be kept in mind there is still no guarantee that the FDA will approve something – even if Phase I to Phase III trials or studies resulted in positive data or results. Sometime the FDA will ask for further studies or clarifications.
Keep in mind that most drug clinical trials will fail to achieve their goals – meaning you should look for clinical stage biotech stocks that have diversified drug pipelines or are building drug platforms that have the potential to treat multiple conditions.
With that said and if you are a risk adverse investor, you would be better off buying established biotech stocks that are beyond the clinical stage with approved drugs, are profitable and have developed drug pipelines. The downside about such biotech stocks is that they are already on Wall Street's radar and the trading screen of every other biotech stock trader/investor out there – meaning you have probably missed the big homerun, share pop or lottery ticket winner.
Clinical Stage Biotech Stock Example: PharmaCyte Biotech
Small cap PharmaCyte Biotech is a good example of a clinical stage biotechnology company that’s probably still off the radar screen of Wall Street and most biotech investors as its still trading on the OTC. PharmaCyte Biotech is focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box.
More specifically, the technology encloses living cells in protective “cocoons” or “capsules” about the size of the head of a pin. The live cells inside the Cell-in-a-Box® capsules are then nourished and thrive while the capsules are in the body and are protected from attack by the body’s immune system because they cannot escape from the capsules and immune system cells cannot enter the capsules and destroy them.
PharmaCyte Biotech’s Cell-in-a-Box encapsulation differs from those produced by others as competitors use substances such as alginate (a seaweed derivative) or chitosan whereas PMCB’s capsules are made principally of cellulose, a bio-inert material in the human body.
For the second half of the year, PharmaCyte Biotech has been busy making various announcements worth noting by investors:
http://pharmacyte.com/
Recent PMCB News
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 08/13/2024 08:37:40 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 07/29/2024 08:05:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 08:59:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 08:58:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 08:58:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 08:58:35 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/30/2024 08:05:04 PM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 05/30/2024 08:05:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/23/2024 08:40:20 PM
- PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease • Business Wire • 05/21/2024 01:00:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 08:38:38 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/06/2024 02:56:28 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 12/15/2023 10:25:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/24/2023 09:00:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:02:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:02:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:01:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:01:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:01:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:00:10 PM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 11/22/2023 09:00:15 PM
- PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women’s Health Innovator Femasys, Inc. • Business Wire • 11/15/2023 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 10:25:09 PM
- PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology • Business Wire • 10/31/2023 01:15:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM